CXCL9 and lung cancer: In addition, we found lower cell motility in the CD8+ T cells in the patients with lung cancer compared to in healthy CD8+ T cells (p < 0.05, Figure 4H), and there were decreased levels of CXCL9 and CXCL10 in the patient’s nonCD8+ PBMCs compared to healthy nonCD8+ PBMCs (p < 0.05, Figure 4I).